Related Experiment Video
Updated: Feb 2, 2026
03:47
Author Spotlight: Workflow for Integrating POCUS Data into EHR for Managing Heart Failure Patients
Published on: July 12, 2024
1.2K
Advanced Heart Failure Management and Transplantation
Avi Levine1, Chhaya Aggarwal Gupta1, Alan Gass2
1Advanced Heart Failure and Cardiac Transplantation, Division of Cardiology, Department of Medicine, Westchester Medical Center, New York Medical College, Macy Pavilion, Suite 100, 100 Woods Road, Valhalla, NY 10595, USA.
Cardiology Clinics
|November 19, 2018
Summary
Hypertrophic cardiomyopathy is a genetic heart condition that can lead to advanced heart failure. Cardiac transplantation is an effective treatment option for patients with end-stage disease, offering encouraging long-term outcomes.
Area of Science:
- Cardiology
- Genetics
- Heart Failure Research
Background:
- Hypertrophic cardiomyopathy (HCM) is a genetic heart disease characterized by diverse clinical presentations.
- Progression to advanced heart failure in HCM can stem from outflow obstruction or intrinsic myocardial fibrosis and dysfunction.
- Conventional heart failure treatments are often ineffective for end-stage HCM patients.
Purpose of the Study:
- To review the management strategies for advanced heart failure in patients with hypertrophic cardiomyopathy.
- To evaluate the efficacy of advanced therapies, specifically left ventricular assist devices (LVADs) and cardiac transplantation, in this patient population.
Main Methods:
- Literature review of studies focusing on hypertrophic cardiomyopathy and end-stage heart failure.
- Analysis of treatment outcomes for LVADs and cardiac transplantation in HCM patients.
Main Results:
- Left ventricular assist device (LVAD) support is infrequently utilized in HCM due to the condition's restrictive physiology.
- Cardiac transplantation demonstrates effectiveness as a treatment for end-stage hypertrophic cardiomyopathy.
- Encouraging long-term outcome data support cardiac transplantation as a viable option for select HCM patients.
Conclusions:
- For patients with end-stage hypertrophic cardiomyopathy, advanced therapies are necessary.
- Cardiac transplantation is a recommended and effective treatment for advanced hypertrophic cardiomyopathy, with positive long-term results.
Related Concept Videos
01:30Heart Failure V: Medical Management
319
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
319
01:29Heart Failure II: Pathophysiology
929
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
929
01:17Pathophysiology of Heart Failure
3.7K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.7K
01:27Heart Failure I: Introduction
886
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
886
01:22Heart Failure VI: Adjunct Therapies
340
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
340
01:22Heart Failure Drugs: Diuretics
971
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
971